三6egne0SeGO 17)32 PMC 5037635 (hutps://www.ncbi.nlm. .gov/pmca 170-02m immunotherany EEBS Letters (2):288 97 PMID 24295643dco -016 01 .030 w.ncbi.nlm.nih.gov/pmc/articles/PMC4856023).Norure Rv 124:25264PMC4856022 3)a.PMID (https://www.ncbi.nlm.ni Keir ME.Ph "D rammed death-1 ligand 1 sspecifically with the B7-1 costimulatory molecule to inhibitT cell responses"(https://www.nc pMID17629517C 517d6i6016Mimm207.0s.0i6ps/oi010106%2 Jimmunt2.07o201 7 on on CDB+T s://wv M (https:/ 74.0 G.Perry C(May 2011)."pilimu 0000000oo-o 75.Lynch TJ,Bon darenko I,Luft A,Serwatowski P.Barlesi F,Chacko R.Seba stian M,Neal J.Lu H illerot JM,Rec 2)."Ipilimu mabin combination with paclita multicenter phase I study"o nal of Clinical o ww.ncbinim 76.Le DT.Lutz E.Uram JN.Sugar EA.Onners B.Solt S.Zheng L,Diaz LA,Donehower RC,Jaffee EM. Laheru DA(September 2 aluation of ipilimumab in combination with allogeneic pancreati MC3 gene in previously treated pa bi.n s://www.ncbi.nlm.nih.gov/pmc/articles/ MC3779 8.PMID23924790l vw.ncbi.nlm.nih. 77."A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced ClinicalTrials.gov"(https://clinicaltrials.gov/ct2/show/NC 70 ne checkpoint blockade in ca Therapy"(hups: Iof Clinical Oncology.33 4080573(https://www.ncbi.n 80573024s59.4358m 19 an Hooren ark P,Di berg A,Black P,Totterman TH,Mangsbo SM PDI wth of murine bladder on Journal ofmm .4721385-39 E.D.A.A es an immunothera py drug for bladder cane er"(https://www.n ytimes.com/2016/05/19/b siness/food-and-drug-admnistration-mmunotherapy-bladder-cancer.) 06s2rme.1sSN0o3624310pswwwoidaogsn0362433R